Enquyst Technologies

Executive Summary

Enquyst Technologies is a private biomanufacturing company based in San Francisco, founded in 2018. The company is developing next-generation bioprocessing solutions aimed at enabling the cost-effective production of high-purity biologics, including complex therapies such as gene and cell therapies. By focusing on continuous manufacturing and novel purification technologies, Enquyst addresses critical bottlenecks in biomanufacturing—namely scalability, purity, and cost—that currently limit patient access to life-saving treatments. The company's platform has the potential to streamline the production of monoclonal antibodies, recombinant proteins, and other biologics, making it a key enabler for the growing pipeline of curative therapies. While still in a relatively early stage, Enquyst's technology aligns with industry trends toward automation and continuous processing, positioning it for partnerships with biopharma companies seeking to reduce manufacturing costs and improve product quality.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Funding Round70% success
• 2027Strategic Partnership with Top Pharma/Biotech50% success
• TBDCommercial Launch of Continuous Manufacturing Platform30% success